PCI Biotech Holding ASA publishes the Annual Report 2021

Oslo, NORWAY


Oslo, Norway, April 28, 2022

The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2021 and the report is attached, in addition to the report according to the European Single Electronic Format (ESEF). The Annual Report 2021 is also available on the company’s website www.pcibiotech.com.

For further information, please contact:        
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo        
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429        
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757

About PCI Biotech        
PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.

The company’s lead programme fimaVacc aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com                
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo            

Forward-looking statements        
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments



Attachments

2021 Annual report PCI Biotech Holding ASA pcibiotechholdingasa-2021-12-31-en